Sugi Predict

Sugi Predict / Compounds / SCHEMBL29508830

SCHEMBL29508830

SCHEMBL29508830

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@H](C)O)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C

nearest known ligand 0.77

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 13/20 0.74
▸ GCGR P47871 8/20 0.74
▸ GIPR P48546 5/20 0.73
▸ CALCR P30988 3/20 0.71
▸ KEAP1 Q14145 1/20 0.71
▸ NPY1R P25929 1/20 0.71
▸ NPY2R P49146 1/20 0.71
▸ NPY4R P50391 1/20 0.71
▸ NPY5R Q15761 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29771728 0.96 GLP1R (0.71) GLP1RGCGRGIPRKEAP1
SCHEMBL31027142 0.96 GLP1R (0.75) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30658306 0.95 KEAP1 (0.72) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30658282 0.95 KEAP1 (0.73) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30473766 0.94 GLP1R (0.79) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30473786 0.94 GLP1R (0.79) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30473804 0.94 GLP1R (0.79) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30473790 0.94 GLP1R (0.79) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL30473796 0.94 GLP1R (0.79) GLP1RGCGRGIPRCALCRKEAP1
SCHEMBL28716445 0.94 GLP1R (0.79) GLP1RGCGRGIPRCALCRKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3970735-B1 USE OF COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BONE LOSS DISORDERS, COMPRISING CYCLO-HISPRO (CHP) AND PARATHYROID HORMONE NOVMETAPHARMA CO LTD (KR) 2025-03-12 — — EP disclosed
CN-113853211-B Use of a composition comprising a cyclic (histidine-proline) dipeptide and parathyroid hormone for preventing, ameliorating or treating bone loss diseases 诺麦塔制药有限公司 2024-10-15 — — CN disclosed
EP-3970735-A1 USE OF COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BONE LOSS DISORDERS, COMPRISING CYCLO-HISPRO (CHP) AND PARATHYROID HORMONE Novmetapharma Co., Ltd. (KR) 2022-03-23 — — EP disclosed
Send feedback